Investigation abut the relationship between systemic sympathetic nerve activity and use of SGLT2 inhibitor in patients with type2 diabetes mellitus.

Phase 3

Recruiting

• Conditions: Type2 diabetes mellitus

• Registration Number: JPRN-UMIN000026335
• Lead Sponsor: Kanazawa university, graduate school of advanced preventive medical science, system biology

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2017-03-01
• Study Completion: 2022-03-31
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

Not provided

Exclusion Criteria

Patients who can't indicate one's intention History of myocardial infarction within 3 months before. Complicated with lung disease renal failure( eGFR<45)

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The comparison of muscle sympathetic nerve activity between baseline and 24 week after implementation of dapagliflozin therapy.

Secondary Outcome Measures

Name	Time	Method
To compare the difference of primary outcome between patients complicated with heart failure and patients without heart failure. To compare the difference of echocardiographic parameters(EF,E/E',etc.) and labor data(BNP,etc.) between baseline and 24 week after implementation of dapagliflozin therapy.